• Date: March 13, 2018

Founded at the Bellvitge Biomedical Research Institute (IDIBELL), ADmit Therapeutics is aiming to develop a diagnostic test to detect Alzheimer's disease in its very early stages.

It is the fifth spin-off that has resulted from the CaixaImpulse programme, in this case from the Kit for early Alzheimer's detection project from 2015, led by Marta Barrachina. Barrachina is the general director of the new company, and is joined by Ramón Reñé and Jordi Gascón as medical advisory board.

The in vitro diagnostic test developed by ADmit Therapeutics determines whether certain mitochondrial biomarkers are present in the blood. These biomarkers can indicate signs of the disease before the brain starts producing the protein aggregates that characterise Alzheimer's. Early diagnosis would allow those affected to start receiving the treatments available to slow down the progress of the disease, as there are still no treatments to reverse it. The company is seeking private investors as a step towards CE certification.

More programme highlights

December 13, 2018

Financing Week brings CaixaImpulse 2018 training to a close

The Financing Week marks the end of the training sessions for leaders of the projects chosen for this year's CaixaImpulse programme.

October 31, 2018

Penultimate week of training sessions for projects in CaixaImpulse 2018

From 6 to 9 November, the leaders of the projects selected to take part in CaixaImpulse 2018 have a date with the third week of training sessions offered under the programme.

October 11, 2018

The CaixaImpulse training programme continues with the Tech Transfer & Valorisation Week

Led by a number of different experts, this training focuses on product development and intellectual property.